% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • jeremybates15 jeremybates15 Jan 22, 2013 10:28 PM Flag

    new fact sheet on website

    There's a new fact sheet on the website. It says "Updated on January 15, 2013."

    The fact sheet asserts that the AEZS-108 trial in endometrial cancer has been "initiated." Their wording is "Pivotal Phase 3 trial initiated in Q1-2013 (not yet recruiting)."

    The perifosine interim analysis is still "expected in Q1-2013." And the AEZS-130 NDA is still "planned in Q1-2013."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the fact sheet:

      Perifosine (oral Akt inhibitor)
      FDA orphan-drug and Fast Track designations, as well as EMA positive Scientific Advice and orphan medicinal product designation.
       Multiple Myeloma
      - Ongoing Phase 3 trial in U.S. with additional sites in Europe and other countries
      - Interim analysis expected in Q1-2013

      AEZS-108 (doxorubicin peptide conjugate)
      Hybrid molecule composed of a synthetic peptide carrier linked to doxorubicin, specifically targeting LHRH receptor expressing tumors.
       Advanced Endometrial Cancer
      - Pivotal Phase 3 trial initiated in Q1-2013 (not yet recruiting)
       Advanced Ovarian Cancer
      - Phase 2 trial completed
       Castration- and Taxane-Resistant Prostate Cancer, Refractory Bladder Cancer and Triple Negative Breast Cancer
      - Ongoing Phase 2 trials

      AEZS-130 (oral ghrelin agonist)
      FDA orphan-drug designation as diagnostic test for growth hormone deficiency.
       Adult Growth Hormone Deficiency (AGHD)
      - Phase 3 trial completed as oral diagnostic test
      - NDA filing planned in Q1-2013
       Cancer-cachexia
      - Ongoing Phase 2A trial in the U.S.

      • 1 Reply to sprypoke
      • Bumping up.

        Three hugely positive events scheduled in the next two months.

        1. AEZS-130 - NDA filing planned in Q1-2013
        2. AEZS-108 - Pivotal Phase 3 trial initiated in Q1-2013. May be a partnership announcement any day.
        3. Perifosine - Interim analysis expected end of Q1-2013 or early April

        Easy double from here with very little risk if one gets out before Perifosine interim analysis. Will be a 4 or 5 bagger with a AEZS 108 partnership and successful Perifosine results.

        Sentiment: Strong Buy

3.44+0.02(+0.58%)Sep 30 3:59 PMEDT